INOVIQ Partners With Sonic Healthcare USA on Ovarian Test
Sonic Healthcare USA gains a licence to validate INOVIQ's EXO-OC blood test for early ovarian cancer detection.
Updated on Nov. 2, 2026 in Cancer
Live Poll
Would you trust a blood test for early ovarian cancer detection if it became available?
INOVIQ has entered a validation and licence option agreement with Sonic Healthcare USA covering EXO-OC, an exosome-based blood test for early detection of ovarian cancer in asymptomatic women. Sonic Healthcare USA was granted a licence to transfer, optimise, and validate the test.
Why it matters
The agreement pairs INOVIQ's EXO-OC test with a leading US laboratory, a step toward potential commercial availability for American women. Ovarian cancer is often diagnosed late, so an early-detection blood test could matter for a disease with high mortality.
The retrospective study reported 100% stage I/II sensitivity and 77% all-stage sensitivity at 99.6% specificity, while an updated algorithm reported 92.3% stage I/II and 92.5% all-stage sensitivity at 98% specificity. These results come from retrospective work, and prospective clinical validation across the US has not yet been reported.
The players
INOVIQ
An Australian diagnostics company developing the exosome-based EXO-OC test using its proprietary EXO-NET technology.
Sonic Healthcare USA
The US arm of Sonic Healthcare, a major international medical laboratory network that operates molecular diagnostics laboratories.
The details
Under the agreement, Sonic Healthcare USA will transfer, optimise, and validate EXO-OC at its molecular diagnostics laboratory in New York state, with an option to pursue a future licence to offer the test as a laboratory developed test. INOVIQ will collect clinical samples across the US in collaboration with ovarian cancer specialists and hospitals.
Timeline
The American Cancer Society estimated 21,010 new US ovarian cancer diagnoses in 2026.
The optimisation and validation program for LDT commercialisation is anticipated to be finalised by early 2028.
Big Picture
EXO-OC builds on the CA-125 blood test, which has long been used in ovarian cancer monitoring, by combining it with multiple exosomal miRNA biomarkers in an AI/machine learning algorithm. The shift from a single-marker approach toward multi-marker blood tests for early detection is the trend this partnership advances.
If the test reaches commercial availability, women in the US could potentially access a blood-based option for early ovarian cancer screening, though current availability is not established in the source. Women with concerns about ovarian cancer should discuss screening options with a clinician.
The takeaway
Early detection remains difficult for ovarian cancer, and blood-based tests are being developed to address that gap. Readers should watch for prospective validation results before drawing conclusions about clinical performance.
Further reading
For more on early detection research, see Cancer coverage on Wisevoter.
Source note: This article includes information reported by Small Caps.
Live Poll
Would you trust a blood test for early ovarian cancer detection if it became available?
